CinRx, a North Industrial Zone Lod, Israel- and Cincinnati, OH-based biopharmaceutical company developing novel therapeutics that address diverse therapeutic areas, completed its $10m Series B round of financing.
Backers included both current and new investors.
The company will use the funds to further advance its broad clinical development pipeline, which is approaching clinical trials in diverse indications, ranging from large markets to orphan indications. CinRx expects to file an Investigational New Drug (IND) application in the first half of 2018 for its most advanced candidate, CIN-102, which is in development for the treatment of gastroparesis.
Led by Jon Isaacsohn, M.D., FACC, Chief Executive Officer and Co-Founder, Catherine Pearce, Co-Founder and Chief Operating Officer, CinRx has developed a pipeline includes four lead candidates addressing substantial needs in gastrointestinal disorders – gastroparesis and irritable bowel syndrome of diarrheal form (IBS-D) – cardiovascular disease, and dermatology, respectively:
– Deuterated domperidone (CIN-102) is a dopamine 2-receptor antagonist in development for gastroparesis, for which IND-enabling studies are ongoing.
– CIN-103 is a novel agent for IBS-D, for which all IND-enabling studies have been completed.
– CIN-105, which is being developed (currently in preclinical stage) for a cardiovascular indication affecting a broad population.
– CIN-101, which is in preclinical stage for a dermatology indication.